These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 17343130)

  • 1. [ADOPT study: which first-line glucose-lowering oral medication in type 2 diabetes?].
    Scheen AJ
    Rev Med Liege; 2007 Jan; 62(1):48-52. PubMed ID: 17343130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
    Kahn SE; Haffner SM; Heise MA; Herman WH; Holman RR; Jones NP; Kravitz BG; Lachin JM; O'Neill MC; Zinman B; Viberti G;
    N Engl J Med; 2006 Dec; 355(23):2427-43. PubMed ID: 17145742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.
    Viberti G; Kahn SE; Greene DA; Herman WH; Zinman B; Holman RR; Haffner SM; Levy D; Lachin JM; Berry RA; Heise MA; Jones NP; Freed MI
    Diabetes Care; 2002 Oct; 25(10):1737-43. PubMed ID: 12351470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT.
    Kahn SE; Lachin JM; Zinman B; Haffner SM; Aftring RP; Paul G; Kravitz BG; Herman WH; Viberti G; Holman RR;
    Diabetes; 2011 May; 60(5):1552-60. PubMed ID: 21415383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.
    Zinman B; Haffner SM; Herman WH; Holman RR; Lachin JM; Kravitz BG; Paul G; Jones NP; Aftring RP; Viberti G; Kahn SE;
    J Clin Endocrinol Metab; 2010 Jan; 95(1):134-42. PubMed ID: 19875477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials.
    Home PD; Kahn SE; Jones NP; Noronha D; Beck-Nielsen H; Viberti G; ;
    Diabetologia; 2010 Sep; 53(9):1838-45. PubMed ID: 20532476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability profile of metformin/glibenclamide combination tablets (Glucovance): a new treatment for the management of type 2 diabetes mellitus.
    Davidson JA; Scheen AJ; Howlett HC
    Drug Saf; 2004; 27(15):1205-16. PubMed ID: 15588116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT).
    Kahn SE; Haffner SM; Viberti G; Herman WH; Lachin JM; Kravitz BG; Yu D; Paul G; Holman RR; Zinman B;
    Diabetes Care; 2010 Jan; 33(1):177-83. PubMed ID: 19808911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postmarketing pharmacovigilance of adverse drug reactions: the case of rosiglitazone in Mexico.
    Reyes-Morales H; Mino-León D; Doubova SV; Flores-Hernández S
    Int J Clin Pharmacol Ther; 2012 Jan; 50(1):1-9. PubMed ID: 22192639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus.
    Ramsdell JW; Braunstein SN; Stephens JM; Bell CF; Botteman MF; Devine ST
    Pharmacoeconomics; 2003; 21(11):819-37. PubMed ID: 12859222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).
    Kahn SE; Zinman B; Lachin JM; Haffner SM; Herman WH; Holman RR; Kravitz BG; Yu D; Heise MA; Aftring RP; Viberti G;
    Diabetes Care; 2008 May; 31(5):845-51. PubMed ID: 18223031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin.
    Maffioli P; Fogari E; D'Angelo A; Perrone T; Derosa G
    Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1113-22. PubMed ID: 23524525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.
    Shearer AT; Bagust A; Ampudia-Blasco FJ; Martínez-Lage Alvarez B; Pérez Escolano I; París G
    Pharmacoeconomics; 2006; 24 Suppl 1():49-59. PubMed ID: 16800162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type 2 diabetes and metformin. First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects.
    Prescrire Int; 2014 Nov; 23(154):269-72. PubMed ID: 25954799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy.
    Wheeler S; Moore K; Forsberg CW; Riley K; Floyd JS; Smith NL; Boyko EJ
    Diabetologia; 2013 Sep; 56(9):1934-43. PubMed ID: 23797633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
    Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pioglitazone, rosiglitazone, and rosiglitazone + metformin: new drugs. Glitazone + oral antidiabetic combination: inadequately evaluated.
    Prescrire Int; 2005 Aug; 14(78):133-9. PubMed ID: 16106595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [ADOPT study. Glitazone controls diabetes progression].
    Einecke D
    MMW Fortschr Med; 2007 Jan; 149(1-2):10, 12, 14. PubMed ID: 17619358
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.